MDP Stock Overview
Operates as a pharmaceutical company in Canada and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Medexus Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$2.40 |
| 52 Week High | CA$3.53 |
| 52 Week Low | CA$1.44 |
| Beta | 1.96 |
| 11 Month Change | 8.60% |
| 3 Month Change | 50.00% |
| 1 Year Change | -28.36% |
| 33 Year Change | -45.08% |
| 5 Year Change | -34.07% |
| Change since IPO | -68.00% |
Recent News & Updates
There May Be Reason For Hope In Medexus Pharmaceuticals' (TSE:MDP) Disappointing Earnings
Aug 19
Medexus Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 10Medexus Pharmaceuticals Inc. (TSE:MDP) Shares Fly 29% But Investors Aren't Buying For Growth
Jul 31Recent updates
There May Be Reason For Hope In Medexus Pharmaceuticals' (TSE:MDP) Disappointing Earnings
Aug 19Medexus Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 10Medexus Pharmaceuticals Inc. (TSE:MDP) Shares Fly 29% But Investors Aren't Buying For Growth
Jul 31The Market Doesn't Like What It Sees From Medexus Pharmaceuticals Inc.'s (TSE:MDP) Revenues Yet
Jun 15Here's Why Medexus Pharmaceuticals (TSE:MDP) Has A Meaningful Debt Burden
Apr 25Revenues Working Against Medexus Pharmaceuticals Inc.'s (TSE:MDP) Share Price Following 26% Dive
Mar 03Medexus Pharmaceuticals Inc.'s (TSE:MDP) Shares Leap 89% Yet They're Still Not Telling The Full Story
Jan 06Here's Why Medexus Pharmaceuticals (TSE:MDP) Has Caught The Eye Of Investors
Oct 11Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?
Sep 11Medexus Pharmaceuticals (TSE:MDP) Use Of Debt Could Be Considered Risky
Jan 19Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?
Sep 22Is Medexus Pharmaceuticals (TSE:MDP) Weighed On By Its Debt Load?
Dec 16Medexus Pharmaceuticals Inc. (TSE:MDP) Analysts Just Cut Their EPS Forecasts Substantially
Aug 21Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?
Aug 04Shareholder Returns
| MDP | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -3.6% | -1.8% | 1.4% |
| 1Y | -28.4% | 38.8% | 14.7% |
Return vs Industry: MDP underperformed the Canadian Pharmaceuticals industry which returned 36% over the past year.
Return vs Market: MDP underperformed the Canadian Market which returned 15.2% over the past year.
Price Volatility
| MDP volatility | |
|---|---|
| MDP Average Weekly Movement | 8.0% |
| Pharmaceuticals Industry Average Movement | 10.4% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in CA Market | 16.7% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: MDP's share price has been volatile over the past 3 months.
Volatility Over Time: MDP's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 82 | Ken d'Entremont | www.medexus.com |
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Medexus Pharmaceuticals Inc. Fundamentals Summary
| MDP fundamental statistics | |
|---|---|
| Market cap | CA$59.14m |
| Earnings (TTM) | CA$1.48m |
| Revenue (TTM) | CA$147.91m |
39.7x
P/E Ratio0.4x
P/S RatioIs MDP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDP income statement (TTM) | |
|---|---|
| Revenue | US$108.78m |
| Cost of Revenue | US$46.15m |
| Gross Profit | US$62.63m |
| Other Expenses | US$61.54m |
| Earnings | US$1.09m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.045 |
| Gross Margin | 57.57% |
| Net Profit Margin | 1.00% |
| Debt/Equity Ratio | 142.2% |
How did MDP perform over the long term?
See historical performance and comparison